Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NanO2 in Large Vessel Occlusion Stroke
NCT06821347Phase 2Not yet recruiting
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- May 2025
- Primary completion
- Jul 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in ischemic stroke comparing NanO2 with Placebo (2 arms). Primary endpoint: Volume of penumbral tissue salvaged based on follow-up imaging compared with pre-treatment penumbral tissue volume at 24 hours. Planned start May 2025; status: not yet recruiting.
02
Drugs
perflenapent
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06821347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06821347.